ND Pharma & Biotech advanced therapies in MS and other myeline-loss related diseases.

Miami. Fla.Scientists at ND Pharma & Biotech subsidiary research company and The Mayfield Clinic for RM are developing advanced therapies for Multiple Sclerosis and other demyelinizating conditions as LAS/ELA, thanks to the most recent advances of a system for Stem Cell obtention, culture and transplantation that is given spectacular promisory results within the Laboratory.
Now, thanks to this system, cientists can detect, extract, culture, enrich, expand and purified neural stem cells pluripotent (BT4) and apply to the treatment of certain conditions of Central Nervous System thru different transplant techniques with impact in myeline-loss diseases as MS Multiple Sclerosis and Amiotrophic Lateral Sclerosis.
The vast majority of clinical management strategies in such diseases are centered in the prevention of neurological damages instead of neurological damages sites repair, (neurons, glia and cells). The method developed is related to the use of certain types of neural pluripotent stem cells in the repair of such damages.
The actual results of such investigation and methods are compiled and stored in the Company´s Repository of Research, Development, Innovation and IP Documents (CRRDIP) as research is evolving to reach a cost-effective product able to be licensed by regulators and comercial cellular lines could appear to the market.